{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:58:54Z","timestamp":1791824334797,"version":"4.3.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Norwegian Community Pharmacy Foundation"},{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Due to a lack of clear symptoms, type 2 diabetes (T2D) can remain undetected for many years. The aim of the study was to explore if Norwegian community pharmacies could identify individuals with a high risk of developing T2D by offering a diabetes risk assessment service. This study also investigated if the service recruited individuals that the national guideline recommends for diabetes risk assessment, and the proportion of participants who had visited their GP at least once a year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>During the inclusion period (September 2016 to the middle of April 2017), pharmacy customers 45 years or older wishing to participate contacted the pharmacy staff. Included participants completed a diabetes risk test and participants with a high risk were offered an HbA1c measurement. At two months after intervention, all participants were followed up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Of the 245 participants, 27% had a high risk of developing T2D. Of these, 46%, 43% and 9% had HbA1c values corresponding to normal (&amp;lt;39 mmol\/mol [5.7%]), prediabetes (39\u201347 mmol\/mol [5.7\u20136.4%]) or above cut-off for diabetes (\u226548 mmol\/mol [\u22656.5%]), respectively. A total of 86% of the participants were in at least one category that the guideline recommends for a diabetes risk assessment, and 88% had visited their GP at least once a year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Norwegian community pharmacies can identify individuals with a high risk of developing T2D by offering a diabetes risk assessment service. Individuals who sought out the service were within the relevant demographics for testing, and a high proportion visited their GP at least once a year.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijpp\/riad055","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T20:38:38Z","timestamp":1690922318000},"page":"512-519","source":"Crossref","is-referenced-by-count":7,"title":["Diabetes risk assessments and HbA1c-measurements in community pharmacies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-1174","authenticated-orcid":false,"given":"Aslaug Johanne","family":"Ris\u00f8y","sequence":"first","affiliation":[{"name":"Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen , Bergen , Norway"},{"name":"Department of Clinical Science, Centre for Pharmacy, Faculty of Medicine, University of Bergen , Bergen , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9454-5188","authenticated-orcid":false,"given":"Reidun Lisbet Skeide","family":"Kjome","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen , Bergen , Norway"},{"name":"Department of Clinical Science, Centre for Pharmacy, Faculty of Medicine, University of Bergen , Bergen , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Sandberg","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen , Bergen , Norway"},{"name":"Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital , Bergen , Norway"},{"name":"Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital , Bergen , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-6620","authenticated-orcid":false,"given":"Una \u00d8rvim","family":"S\u00f8lvik","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, Faculty of Medicine, University of Bergen , Bergen , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2023093018460758500_CIT0001","first-page":"271","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume-title":"Diabetes Res Clin Pract","author":"Cho","year":"2018"},{"key":"2023093018460758500_CIT0002","article-title":"How many people have diabetes in Norway in 2020","volume-title":"Tidsskr Nor Laegeforen","author":"Stene","year":"2020"},{"key":"2023093018460758500_CIT0003","first-page":"1668","article-title":"Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence","volume-title":"Diabetes Care","author":"Porta","year":"2014"},{"key":"2023093018460758500_CIT0004","first-page":"2192","article-title":"Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009","volume-title":"Diabetologia","author":"Simmons","year":"2017"},{"key":"2023093018460758500_CIT0005","first-page":"2200","article-title":"Screening for type 2 diabetes: do screen-detected cases fare better","volume-title":"Diabetologia","author":"Feldman","year":"2017"},{"key":"2023093018460758500_CIT0006","first-page":"326","article-title":"Cost effectiveness of type 2 diabetes screening: A systematic review","volume":"30","author":"Najafi","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"2023093018460758500_CIT0007","first-page":"1741","article-title":"Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial","volume-title":"Lancet","author":"Simmons","year":"2012"},{"key":"2023093018460758500_CIT0008","first-page":"383","article-title":"The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important","volume-title":"Prim Care Diabetes","author":"Khunti","year":"2018"},{"key":"2023093018460758500_CIT0009","year":"2016"},{"key":"2023093018460758500_CIT0010","first-page":"80","article-title":"Community pharmacy type 2 diabetes risk assessment: demographics and risk results","volume-title":"Int J Pharm Pract","author":"Twigg","year":"2015"},{"key":"2023093018460758500_CIT0011","first-page":"1227","article-title":"Comparison of two methods for assessing diabetes risk in a pharmacy setting in Australia","volume-title":"BMC Public Health","author":"Kilkenny","year":"2014"},{"key":"2023093018460758500_CIT0012","first-page":"1","article-title":"Opportunistic risk screening for type 2 diabetes: exploring of application of diabetes risk assessment tool in community pharmacy in Australia and Thailand","volume-title":"Value Health Reg Issues","author":"Thoopputra","year":"2016"},{"key":"2023093018460758500_CIT0013","first-page":"e0191316","article-title":"Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes\u2014a feasibility study","volume-title":"PLoS One","author":"Risoy","year":"2018"},{"key":"2023093018460758500_CIT0014","first-page":"387","article-title":"Detection of people at risk of diabetes in community pharmacies of Pontevedra (Spain) (DEDIPO)","volume-title":"Endocrinol Nutr (English Ed)","author":"Fornos-P\u00e9rez","year":"2016"},{"key":"2023093018460758500_CIT0015","first-page":"30","article-title":"Diabetes screening through community pharmacies in England: a cost-effectiveness study","volume-title":"Pharmacy","author":"Wright","year":"2019"},{"key":"2023093018460758500_CIT0016","first-page":"350","article-title":"Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice","volume-title":"BMC Public Health","author":"Park","year":"2008"},{"key":"2023093018460758500_CIT0017","first-page":"603","article-title":"Emotional impact of screening: a systematic review and meta-analysis","volume-title":"BMC Public Health","author":"Collins","year":"2011"},{"key":"2023093018460758500_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876524601306010001","article-title":"Screening for type 2 diabetes in adults: an updated systematic review","volume":"6","author":"Sherifali","year":"2013","journal-title":"Open Diabetes J"},{"key":"2023093018460758500_CIT0019","author":"The Norwegian Organization for Quality Improvement of Laboratory Examinations [Internet]"},{"key":"2023093018460758500_CIT0020","first-page":"753","article-title":"Quality control of Norwegian pharmacy HbA1c testing: a modest beginning","volume-title":"J Diabetes Sci Technol","author":"S\u00f8lvik","year":"2018"},{"key":"2023093018460758500_CIT0021","article-title":"Quantitative measurement of hemoglobin A1c on the DCA vantage point-of-care analyzer as a diagnostic test for diabetes: an internal validation study","author":"Zercher"},{"key":"2023093018460758500_CIT0022","first-page":"725","article-title":"The diabetes risk score: a practical tool to predict type 2 diabetes risk","volume-title":"Diabetes Care","author":"Lindstrom","year":"2003"},{"key":"2023093018460758500_CIT0023","first-page":"887","article-title":"The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting","volume-title":"Diabet Med","author":"Gray","year":"2010"},{"key":"2023093018460758500_CIT0024","first-page":"2","volume-title":"ISO 22870:2005 Standard. Point-of-Care Testing (POCT)\u2014Requirements for Quality and Competence","author":"International Organization for Standardization","year":"2006"},{"key":"2023093018460758500_CIT0025","volume-title":"Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline. Report POCT07-A","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"2023093018460758500_CIT0026","first-page":"943","article-title":"Laboratory testing in pharmacies","volume-title":"Clin Chem Lab Med","author":"Lippi","year":"2010"},{"key":"2023093018460758500_CIT0027","first-page":"679","article-title":"Pharmacists in the laboratory space: friends or foes","volume-title":"Clin Chem","author":"Gronowski","year":"2016"},{"key":"2023093018460758500_CIT0028","author":"Statistics Norway"},{"key":"2023093018460758500_CIT0029","author":"Statistics Norway","year":"2022"},{"key":"2023093018460758500_CIT0030","first-page":"339","article-title":"Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy","volume-title":"Diabetes Res Clin Pract","author":"Krass","year":"2007"},{"key":"2023093018460758500_CIT0031","author":"Statistics Norway"},{"key":"2023093018460758500_CIT0032","first-page":"e000217","article-title":"Impact of sex and age on the performance of FINDRISC: the HUNT Study in Norway","volume-title":"BMJ Open Diabetes Res Care","author":"Jolle","year":"2016"},{"key":"2023093018460758500_CIT0033","first-page":"1259","article-title":"Pharmacists\u2019 experience of a diabetes risk-assessment service and analytical quality control in community pharmacies\u2014a focus-group study","volume-title":"Res Social Adm Pharm","author":"Risoy","year":"2021"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/31\/5\/512\/51821149\/riad055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/31\/5\/512\/51821149\/riad055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T18:46:54Z","timestamp":1696099614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/31\/5\/512\/7234918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riad055","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,8,1]]}}}